CTNM

Contineum Therapeutics Stock Analysis

AI Rating

Neutral
  • Quality0/10
  • Growth↓ 0/10
  • Momentum↑ 9/10
Contineum Therapeutics sales and earnings growth
CTNM Growth
Low
  • Revenue Y/Y↓ 0.00%
  • EPS Y/Y↑ 53.59%
  • FCF Y/Y↓ -55.45%
Contineum Therapeutics gross and profit margin trends
CTNM Profitability
Low
  • Gross margin ↓ 0.00%
  • EPS margin↓ 0.00%
  • ROIC↓ -35.60%
Contineum Therapeutics net debt vs free cash flow
CTNM Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Contineum Therapeutics stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

More Biotechnology stocks ↗